Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma
Latest Information Update: 04 Nov 2022
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms CARAMEL
- 31 Oct 2022 Planned End Date changed from 1 Aug 2023 to 31 May 2026.
- 31 Oct 2022 Planned primary completion date changed from 1 Aug 2023 to 31 May 2026.
- 31 Oct 2022 Planned initiation date changed from 1 Oct 2021 to 1 Jan 2023.